Paper Details

  1. Home
  2. Paper Details

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

Author: BakishDavid, BoseAnjana, ChenChangzheng, GommollCarl, GreenbergWilliam M, KhanArif, LiebowitzMichael, NunezRene

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A 10-week, double-blind, placebo-controlled study of levomilnacipran ER in patients with major depressive disorder found that levomilnacipran ER at doses of 40 mg/day and 80 mg/day demonstrated efficacy in improving both symptomatic and functional measures of MDD compared to placebo. Levomilnacipran ER was generally well tolerated, although more patients in the treatment group prematurely exited the study due to adverse events.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Major depressive disorder (MDD) is a global health concern. This study examined the efficacy, safety and tolerability of an extended-release (ER) formulation of levomilnacipran, an antidepressant approved for the treatment of MDD in adults. METHODS: This 10-week (1-week placebo run-in p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868664/

データ提供：米国国立医学図書館（NLM）

Major Depressive Disorder: A Desert of Despair

Major depressive disorder (MDD) is a challenging and debilitating condition that can feel like wandering through a vast and desolate desert of despair. This study investigates the effectiveness and safety of levomilnacipran, an antidepressant, in treating MDD. The researchers conducted a clinical trial to assess the efficacy of levomilnacipran in reducing depressive symptoms and improving overall well-being.

Finding Hope in the Desert: Levomilnacipran for Major Depressive Disorder

The study found that levomilnacipran was effective in reducing depressive symptoms in patients with MDD, providing a beacon of hope for those struggling with this condition. The findings suggest that levomilnacipran could be a valuable tool in the treatment of MDD, offering a path towards recovery and improved quality of life. This study is like finding a wellspring of fresh water in the heart of the desert, offering relief and sustenance for those in need.

A Promise for Recovery: Exploring the Potential of Levomilnacipran

This study provides a promising indication that levomilnacipran can help alleviate the symptoms of MDD, offering a potential path towards recovery. It's important to note, however, that further research is needed to fully understand its long-term effects and benefits. Just as a traveler carefully explores a new oasis, seeking to understand its potential and dangers, so too do researchers continue to study the nuances of levomilnacipran and its role in treating MDD.

Dr.Camel's Conclusion

Major depressive disorder is a complex and challenging condition. This study provides evidence that levomilnacipran can be an effective treatment option, offering a potential path towards recovery. However, it's important to remember that each individual's journey through the desert of depression is unique, requiring careful consideration and a personalized approach to treatment.

Date :
  1. Date Completed 2015-04-02
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24144196

DOI: Digital Object Identifier

PMC3868664

Related Literature

Article Analysis
・Effects of levomilnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.